Biora Therapeutics Reports Lower-Than-Expected GAAP EPS But Beats Estimates on Revenue
March 31, 2023
Trending News 🌥️
Biora Therapeutics ($NASDAQ:BIOR) recently reported their GAAP EPS (Earnings Per Share), which was lower than anticipated by $0.19. Its revenue of $0.14M was, however, higher than expected by $0.08M, providing a much-needed boost for the company. The company’s primary goal is to create innovative therapies that will have profound effects on the lives of those affected by such illnesses. Despite the lower-than-expected GAAP EPS, investors remain positive about the future of Biora Therapeutics and its potential to develop effective treatments for rare pediatric diseases.
Price History
The company’s stock opened at $2.7 and closed at $2.7, up 0.8% from the prior closing price of $2.6. This was a positive sign for investors and analysts alike. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Biora Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 0.73 | -117.31 | -11773.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Biora Therapeutics. More…
| Operations | Investing | Financing |
| -93.44 | -0.51 | 76.32 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Biora Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 62.61 | 160.06 | -12.88 |
Key Ratios Snapshot
Some of the financial key ratios for Biora Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -78.6% | – | -8304.0% |
| FCF Margin | ROE | ROA |
| -12970.4% | 38.9% | -60.2% |
Analysis
At GoodWhale, we’ve conducted an in-depth analysis of BIORA THERAPEUTICS‘ financials. We’ve rated the company as a high risk in terms of financial and business aspects. Furthermore, our risk detection software has detected 4 risk warnings in BIORA THERAPEUTICS’ balance sheet, cashflow statement, non financial, and financial journal. If you’d like to learn more about these risk warnings, you can register with us to get a deeper look into the company’s financials. More…
Peers
The competition in the field of cancer therapeutics is heating up, with Biora Therapeutics Inc taking on NuCana PLC, GT Biopharma Inc, and CytomX Therapeutics Inc. While each company has its own unique approach to cancer treatment, they are all striving to be the best in the field. May the best company win!
– NuCana PLC ($NASDAQ:NCNA)
NuCana PLC is a pharmaceutical company that focuses on the development and commercialization of cancer treatments. The company has a market capitalization of $52.2 million and a return on equity of -44.76%. NuCana PLC’s products are designed to improve the treatment of cancer by targeting the disease at the cellular level. The company’s products are in various stages of development, including clinical trials.
– GT Biopharma Inc ($NASDAQ:GTBP)
ACGT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapies for the treatment of cancer. The company’s lead product candidates are ACGT087, a monoclonal antibody targeting CD73, and ACGT141, a monoclonal antibody targeting CTLA-4. ACGT Biopharma Inc is headquartered in San Diego, California.
– CytomX Therapeutics Inc ($NASDAQ:CTMX)
CytomX Therapeutics Inc is a clinical-stage biopharmaceutical company developing a novel class of investigational antibody therapeutics based on its Probody platform. The Probody platform is designed to improve the therapeutic index of antibodies by targeting them to cancer cells while limiting exposure to healthy tissues. CytomX’s lead product candidate, CX-072, is an anti-CD166 Probody therapeutic antibody in Phase 1 clinical testing for the treatment of solid tumors.
Summary
Revenue for the quarter was $0.14 million, beating analysts’ estimates by $0.08 million. Despite the beat on revenue, the stock has seen a considerable drop from its previous levels as a result of the earnings miss. Investors should closely monitor the company’s future performance to determine whether the stock’s current levels are a good buying opportunity. In the meantime, investors should be cognizant of the risks associated with investing in Biora Therapeutics, including potential challenges to its operational and financial growth.
